Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype

Andrea Cortese, Raffaella Lombardi, Chiara Briani, Ilaria Callegari, Luana Benedetti, Fiore Manganelli, Marco Luigetti, Sergio Ferrari, Angelo M Clerici, Girolama Alessandra Marfia, Andrea Rigamonti, Marinella Carpo, Raffaella Fazio, Massimo Corbo, Anna Mazzeo, Fabio Giannini, Giuseppe Cosentino, Elisabetta Zardini, Riccardo Currò, Matteo GastaldiElisa Vegezzi, Enrico Alfonsi, Angela Berardinelli, Ludivine Kouton, Constance Manso, Claudia Giannotta, Pietro Doneddu, Patrizia Dacci, Laura Piccolo, Marta Ruiz, Alessandro Salvalaggio, Chiara De Michelis, Emanuele Spina, Antonietta Topa, Giulia Bisogni, Angela Romano, Sara Mariotto, Giorgia Mataluni, Federica Cerri, Claudia Stancanelli, Mario Sabatelli, Angelo Schenone, Enrico Marchioni, Giuseppe Lauria, Eduardo Nobile-Orazio, Jérôme Devaux, Diego Franciotta

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/paranodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cohort, compare clinical features in seronegative vs seropositive patients, and gather evidence of their isotype-specific pathogenic role.

METHODS: Antibodies to neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1) were detected with ELISA and/or cell-based assay. Antibody pathogenicity was tested by immunohistochemistry on skin biopsy, intraneural injection, and cell aggregation assay.

RESULTS: Of 342 patients with CIDP, 19 (5.5%) had antibodies against Nfasc155 (n = 9), Nfasc140/186 and Nfasc155 (n = 1), CNTN1 (n = 3), and Caspr1 (n = 6). Antibodies were absent from healthy and disease controls, including neuropathies of different causes, and were mostly detected in patients with European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) definite CIDP (n = 18). Predominant antibody isotypes were immunoglobulin G (IgG)4 (n = 13), IgG3 (n = 2), IgG1 (n = 2), or undetectable (n = 2). IgG4 antibody-associated phenotypes included onset before 30 years, severe neuropathy, subacute onset, tremor, sensory ataxia, and poor response to intravenous immunoglobulin (IVIG). Immunosuppressive treatments, including rituximab, cyclophosphamide, and methotrexate, proved effective if started early in IVIG-resistant IgG4-seropositive cases. Five patients with an IgG1, IgG3, or undetectable isotype showed clinical features indistinguishable from seronegative patients, including good response to IVIG. IgG4 autoantibodies were associated with morphological changes at paranodes in patients' skin biopsies. We also provided preliminary evidence from a single patient about the pathogenicity of anti-Caspr1 IgG4, showing their ability to penetrate paranodal regions and disrupt the integrity of the Nfasc155/CNTN1/Caspr1 complex.

CONCLUSIONS: Our findings confirm previous data on the tight clinico-serological correlation between antibodies to nodal/paranodal proteins and CIDP. Despite the low prevalence, testing for their presence and isotype could ultimately be part of the diagnostic workup in suspected inflammatory demyelinating neuropathy to improve diagnostic accuracy and guide treatment.

CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that antibodies to nodal/paranodal proteins identify patients with CIDP (sensitivity 6%, specificity 100%).

Original languageEnglish
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Contactin 1
Contactins
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Immunoglobulin Isotypes
Immunoglobulin G
Nodal Protein
Antibodies
Proteins
Intravenous Immunoglobulins
Virulence
Biopsy
Cell Aggregation
Skin
Tremor
Ataxia
Immunosuppressive Agents
Methotrexate
Autoantibodies
Cyclophosphamide

Cite this

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP : Clinical relevance of IgG isotype. / Cortese, Andrea; Lombardi, Raffaella; Briani, Chiara; Callegari, Ilaria; Benedetti, Luana; Manganelli, Fiore; Luigetti, Marco; Ferrari, Sergio; Clerici, Angelo M; Marfia, Girolama Alessandra; Rigamonti, Andrea; Carpo, Marinella; Fazio, Raffaella; Corbo, Massimo; Mazzeo, Anna; Giannini, Fabio; Cosentino, Giuseppe; Zardini, Elisabetta; Currò, Riccardo; Gastaldi, Matteo; Vegezzi, Elisa; Alfonsi, Enrico; Berardinelli, Angela; Kouton, Ludivine; Manso, Constance; Giannotta, Claudia; Doneddu, Pietro; Dacci, Patrizia; Piccolo, Laura; Ruiz, Marta; Salvalaggio, Alessandro; De Michelis, Chiara; Spina, Emanuele; Topa, Antonietta; Bisogni, Giulia; Romano, Angela; Mariotto, Sara; Mataluni, Giorgia; Cerri, Federica; Stancanelli, Claudia; Sabatelli, Mario; Schenone, Angelo; Marchioni, Enrico; Lauria, Giuseppe; Nobile-Orazio, Eduardo; Devaux, Jérôme; Franciotta, Diego.

In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 7, No. 1, 01.2020.

Research output: Contribution to journalArticle

Cortese, A, Lombardi, R, Briani, C, Callegari, I, Benedetti, L, Manganelli, F, Luigetti, M, Ferrari, S, Clerici, AM, Marfia, GA, Rigamonti, A, Carpo, M, Fazio, R, Corbo, M, Mazzeo, A, Giannini, F, Cosentino, G, Zardini, E, Currò, R, Gastaldi, M, Vegezzi, E, Alfonsi, E, Berardinelli, A, Kouton, L, Manso, C, Giannotta, C, Doneddu, P, Dacci, P, Piccolo, L, Ruiz, M, Salvalaggio, A, De Michelis, C, Spina, E, Topa, A, Bisogni, G, Romano, A, Mariotto, S, Mataluni, G, Cerri, F, Stancanelli, C, Sabatelli, M, Schenone, A, Marchioni, E, Lauria, G, Nobile-Orazio, E, Devaux, J & Franciotta, D 2020, 'Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype', Neurology: Neuroimmunology and NeuroInflammation, vol. 7, no. 1. https://doi.org/10.1212/NXI.0000000000000639
Cortese, Andrea ; Lombardi, Raffaella ; Briani, Chiara ; Callegari, Ilaria ; Benedetti, Luana ; Manganelli, Fiore ; Luigetti, Marco ; Ferrari, Sergio ; Clerici, Angelo M ; Marfia, Girolama Alessandra ; Rigamonti, Andrea ; Carpo, Marinella ; Fazio, Raffaella ; Corbo, Massimo ; Mazzeo, Anna ; Giannini, Fabio ; Cosentino, Giuseppe ; Zardini, Elisabetta ; Currò, Riccardo ; Gastaldi, Matteo ; Vegezzi, Elisa ; Alfonsi, Enrico ; Berardinelli, Angela ; Kouton, Ludivine ; Manso, Constance ; Giannotta, Claudia ; Doneddu, Pietro ; Dacci, Patrizia ; Piccolo, Laura ; Ruiz, Marta ; Salvalaggio, Alessandro ; De Michelis, Chiara ; Spina, Emanuele ; Topa, Antonietta ; Bisogni, Giulia ; Romano, Angela ; Mariotto, Sara ; Mataluni, Giorgia ; Cerri, Federica ; Stancanelli, Claudia ; Sabatelli, Mario ; Schenone, Angelo ; Marchioni, Enrico ; Lauria, Giuseppe ; Nobile-Orazio, Eduardo ; Devaux, Jérôme ; Franciotta, Diego. / Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP : Clinical relevance of IgG isotype. In: Neurology: Neuroimmunology and NeuroInflammation. 2020 ; Vol. 7, No. 1.
@article{8493ca4a5c224040bd758802ea787ce5,
title = "Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype",
abstract = "OBJECTIVE: To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/paranodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cohort, compare clinical features in seronegative vs seropositive patients, and gather evidence of their isotype-specific pathogenic role.METHODS: Antibodies to neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1) were detected with ELISA and/or cell-based assay. Antibody pathogenicity was tested by immunohistochemistry on skin biopsy, intraneural injection, and cell aggregation assay.RESULTS: Of 342 patients with CIDP, 19 (5.5{\%}) had antibodies against Nfasc155 (n = 9), Nfasc140/186 and Nfasc155 (n = 1), CNTN1 (n = 3), and Caspr1 (n = 6). Antibodies were absent from healthy and disease controls, including neuropathies of different causes, and were mostly detected in patients with European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) definite CIDP (n = 18). Predominant antibody isotypes were immunoglobulin G (IgG)4 (n = 13), IgG3 (n = 2), IgG1 (n = 2), or undetectable (n = 2). IgG4 antibody-associated phenotypes included onset before 30 years, severe neuropathy, subacute onset, tremor, sensory ataxia, and poor response to intravenous immunoglobulin (IVIG). Immunosuppressive treatments, including rituximab, cyclophosphamide, and methotrexate, proved effective if started early in IVIG-resistant IgG4-seropositive cases. Five patients with an IgG1, IgG3, or undetectable isotype showed clinical features indistinguishable from seronegative patients, including good response to IVIG. IgG4 autoantibodies were associated with morphological changes at paranodes in patients' skin biopsies. We also provided preliminary evidence from a single patient about the pathogenicity of anti-Caspr1 IgG4, showing their ability to penetrate paranodal regions and disrupt the integrity of the Nfasc155/CNTN1/Caspr1 complex.CONCLUSIONS: Our findings confirm previous data on the tight clinico-serological correlation between antibodies to nodal/paranodal proteins and CIDP. Despite the low prevalence, testing for their presence and isotype could ultimately be part of the diagnostic workup in suspected inflammatory demyelinating neuropathy to improve diagnostic accuracy and guide treatment.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that antibodies to nodal/paranodal proteins identify patients with CIDP (sensitivity 6{\%}, specificity 100{\%}).",
author = "Andrea Cortese and Raffaella Lombardi and Chiara Briani and Ilaria Callegari and Luana Benedetti and Fiore Manganelli and Marco Luigetti and Sergio Ferrari and Clerici, {Angelo M} and Marfia, {Girolama Alessandra} and Andrea Rigamonti and Marinella Carpo and Raffaella Fazio and Massimo Corbo and Anna Mazzeo and Fabio Giannini and Giuseppe Cosentino and Elisabetta Zardini and Riccardo Curr{\`o} and Matteo Gastaldi and Elisa Vegezzi and Enrico Alfonsi and Angela Berardinelli and Ludivine Kouton and Constance Manso and Claudia Giannotta and Pietro Doneddu and Patrizia Dacci and Laura Piccolo and Marta Ruiz and Alessandro Salvalaggio and {De Michelis}, Chiara and Emanuele Spina and Antonietta Topa and Giulia Bisogni and Angela Romano and Sara Mariotto and Giorgia Mataluni and Federica Cerri and Claudia Stancanelli and Mario Sabatelli and Angelo Schenone and Enrico Marchioni and Giuseppe Lauria and Eduardo Nobile-Orazio and J{\'e}r{\^o}me Devaux and Diego Franciotta",
note = "Copyright {\circledC} 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",
year = "2020",
month = "1",
doi = "10.1212/NXI.0000000000000639",
language = "English",
volume = "7",
journal = "Neurology: Neuroimmunology and NeuroInflammation",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP

T2 - Clinical relevance of IgG isotype

AU - Cortese, Andrea

AU - Lombardi, Raffaella

AU - Briani, Chiara

AU - Callegari, Ilaria

AU - Benedetti, Luana

AU - Manganelli, Fiore

AU - Luigetti, Marco

AU - Ferrari, Sergio

AU - Clerici, Angelo M

AU - Marfia, Girolama Alessandra

AU - Rigamonti, Andrea

AU - Carpo, Marinella

AU - Fazio, Raffaella

AU - Corbo, Massimo

AU - Mazzeo, Anna

AU - Giannini, Fabio

AU - Cosentino, Giuseppe

AU - Zardini, Elisabetta

AU - Currò, Riccardo

AU - Gastaldi, Matteo

AU - Vegezzi, Elisa

AU - Alfonsi, Enrico

AU - Berardinelli, Angela

AU - Kouton, Ludivine

AU - Manso, Constance

AU - Giannotta, Claudia

AU - Doneddu, Pietro

AU - Dacci, Patrizia

AU - Piccolo, Laura

AU - Ruiz, Marta

AU - Salvalaggio, Alessandro

AU - De Michelis, Chiara

AU - Spina, Emanuele

AU - Topa, Antonietta

AU - Bisogni, Giulia

AU - Romano, Angela

AU - Mariotto, Sara

AU - Mataluni, Giorgia

AU - Cerri, Federica

AU - Stancanelli, Claudia

AU - Sabatelli, Mario

AU - Schenone, Angelo

AU - Marchioni, Enrico

AU - Lauria, Giuseppe

AU - Nobile-Orazio, Eduardo

AU - Devaux, Jérôme

AU - Franciotta, Diego

N1 - Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

PY - 2020/1

Y1 - 2020/1

N2 - OBJECTIVE: To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/paranodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cohort, compare clinical features in seronegative vs seropositive patients, and gather evidence of their isotype-specific pathogenic role.METHODS: Antibodies to neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1) were detected with ELISA and/or cell-based assay. Antibody pathogenicity was tested by immunohistochemistry on skin biopsy, intraneural injection, and cell aggregation assay.RESULTS: Of 342 patients with CIDP, 19 (5.5%) had antibodies against Nfasc155 (n = 9), Nfasc140/186 and Nfasc155 (n = 1), CNTN1 (n = 3), and Caspr1 (n = 6). Antibodies were absent from healthy and disease controls, including neuropathies of different causes, and were mostly detected in patients with European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) definite CIDP (n = 18). Predominant antibody isotypes were immunoglobulin G (IgG)4 (n = 13), IgG3 (n = 2), IgG1 (n = 2), or undetectable (n = 2). IgG4 antibody-associated phenotypes included onset before 30 years, severe neuropathy, subacute onset, tremor, sensory ataxia, and poor response to intravenous immunoglobulin (IVIG). Immunosuppressive treatments, including rituximab, cyclophosphamide, and methotrexate, proved effective if started early in IVIG-resistant IgG4-seropositive cases. Five patients with an IgG1, IgG3, or undetectable isotype showed clinical features indistinguishable from seronegative patients, including good response to IVIG. IgG4 autoantibodies were associated with morphological changes at paranodes in patients' skin biopsies. We also provided preliminary evidence from a single patient about the pathogenicity of anti-Caspr1 IgG4, showing their ability to penetrate paranodal regions and disrupt the integrity of the Nfasc155/CNTN1/Caspr1 complex.CONCLUSIONS: Our findings confirm previous data on the tight clinico-serological correlation between antibodies to nodal/paranodal proteins and CIDP. Despite the low prevalence, testing for their presence and isotype could ultimately be part of the diagnostic workup in suspected inflammatory demyelinating neuropathy to improve diagnostic accuracy and guide treatment.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that antibodies to nodal/paranodal proteins identify patients with CIDP (sensitivity 6%, specificity 100%).

AB - OBJECTIVE: To assess the prevalence and isotypes of anti-nodal/paranodal antibodies to nodal/paranodal proteins in a large chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cohort, compare clinical features in seronegative vs seropositive patients, and gather evidence of their isotype-specific pathogenic role.METHODS: Antibodies to neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1) were detected with ELISA and/or cell-based assay. Antibody pathogenicity was tested by immunohistochemistry on skin biopsy, intraneural injection, and cell aggregation assay.RESULTS: Of 342 patients with CIDP, 19 (5.5%) had antibodies against Nfasc155 (n = 9), Nfasc140/186 and Nfasc155 (n = 1), CNTN1 (n = 3), and Caspr1 (n = 6). Antibodies were absent from healthy and disease controls, including neuropathies of different causes, and were mostly detected in patients with European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) definite CIDP (n = 18). Predominant antibody isotypes were immunoglobulin G (IgG)4 (n = 13), IgG3 (n = 2), IgG1 (n = 2), or undetectable (n = 2). IgG4 antibody-associated phenotypes included onset before 30 years, severe neuropathy, subacute onset, tremor, sensory ataxia, and poor response to intravenous immunoglobulin (IVIG). Immunosuppressive treatments, including rituximab, cyclophosphamide, and methotrexate, proved effective if started early in IVIG-resistant IgG4-seropositive cases. Five patients with an IgG1, IgG3, or undetectable isotype showed clinical features indistinguishable from seronegative patients, including good response to IVIG. IgG4 autoantibodies were associated with morphological changes at paranodes in patients' skin biopsies. We also provided preliminary evidence from a single patient about the pathogenicity of anti-Caspr1 IgG4, showing their ability to penetrate paranodal regions and disrupt the integrity of the Nfasc155/CNTN1/Caspr1 complex.CONCLUSIONS: Our findings confirm previous data on the tight clinico-serological correlation between antibodies to nodal/paranodal proteins and CIDP. Despite the low prevalence, testing for their presence and isotype could ultimately be part of the diagnostic workup in suspected inflammatory demyelinating neuropathy to improve diagnostic accuracy and guide treatment.CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that antibodies to nodal/paranodal proteins identify patients with CIDP (sensitivity 6%, specificity 100%).

U2 - 10.1212/NXI.0000000000000639

DO - 10.1212/NXI.0000000000000639

M3 - Article

C2 - 31753915

VL - 7

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 1

ER -